The proportion of anti-MDA5 Abs positive patients among CADM ranges from 23% to 100%, depending on the cohorts (Table 1) (4–7, 9–14, 17, 19). The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.